Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A shot in the arm for cancer vaccines?

Nature volume 464, pages 1110–1111 (2010)Cite this article

Subjects

Researchers anxiously await a decision by US regulators on a controversial cancer therapy.

In the early 1990s, immunologist Edgar Engleman of California's Stanford University School of Medicine thought he had discovered a way to treat cancer using a vaccine that harnessed the body's immune cells. He co-founded a company — later named Dendreon — in 1992 to develop the vaccine, predicting that it would reach patients within a few years. "We were so naïve," he says. "We didn't know what to expect."

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

NRDD: Rethinking therapeutic cancer vaccines

Related external links

Cancer vaccines

Dendreon

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ledford, H. A shot in the arm for cancer vaccines?. Nature 464, 1110–1111 (2010). https://doi.org/10.1038/4641110a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/4641110a

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer